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ABSTRACT
Despite several improvements in term of diagnosis and prevention, 
ischemic heart disease still represents one of the principal worldwide 
causes of death. Cardiac progenitor cells (CPCs) based therapy is 
considered a valid alternative to heart transplant, but several issues 
concerning the transplanted cells viability, retention and therapeutic 
effect need to be solved. Tissue engineering, mixing synthetic or natural 
polymers with injected cells, could represent the way through which 
overcomes shortages and set up an effective cardiac regenerative 
therapy. Nowadays, it is well known that cardiac extracellular matrix 
(ECM) provides structural and functional integrity, affects cardiac 
function, development and physiologic repair. In this optic, ECM and 
ECM-like materials represent functional and biocompatible tools with 
a great potential to serve as natural or nature-mimicking scaffolds in 
the field of regenerative medicine. The aim of the present work is to 
provide an overview on the state of the art and recent advantages on 
CPCs and scaffold-based therapy for heart regeneration.
Keywords: cardiac progenitor cells; ECM; heart regeneration; tissue 
engineering; biomaterials
1 INTRODUCTION
Despite considerable achievements in term of early diagnosis and 
prevention, ischemic heart disease still represents the leading cause 
of death and disability worldwide and its frequency is increasing. In 
2018, it has been established that ischemic heart disease accounts for 
almost 1.8 million annual deaths [1]. Nowadays, heart transplantation 
represents the only successful therapeutic approach for end-stage 
heart failure (HF) patients. Unfortunately, organ availability and 
immunological issues heavily hinder this strategy. The need to establish 
effective therapies, to improve survival and quality of life of the patients, 
https://mo.hapres.com
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has led researchers to investigate and develop 
alternative therapies able to protect, regenerate and 
functionally restore the damaged myocardium. The 
mammalian heart has been considered, for a long 
time, as a terminally differentiated organ incapable 
of regenerating after injury. In recent years, many 
evidences demonstrated that cardiomyocytes, during 
aging and after injury, are able to reentry in the cell 
cycle and promote cell renewal [2,3]. In addition, it 
has been identified the presence of several resident 
cardiac progenitor cells (CPCs) population that, after 
myocardial infarction (MI), are able to proliferate and 
differentiate into the cardiac lineages [4]. Unfortunately, 
inflammatory processes following cardiac injury, in 
addition to the unsuitable ischemic microenvironment 
and the lack of oxygen, are able to affect this 
endogenous regenerative process exacerbating 
tissue damages and promoting adverse remodeling. 
Accordingly, cardiac cell therapy (CCT) approach, 
based on isolation, expansion and injection of 
CPCs, might be a valid alternative to promote and 
support heart regeneration [5,6]. However, despite the 
encouraging preclinical and clinical results, these 
treatments have shown very limited improvement in 
the long term [7–9]. In fact, it has been demonstrated 
that many injected cells are lost within few hours 
after injection and only the 5–10% can be detected 
after one day in the damaged myocardium [10,11]. The 
limited engraftment and the subsequent reduced 
proliferation and differentiation potential of the 
transplanted cells, due to the interaction between 
injected CPCs, extracellular matrix (ECM) components 
and the local tissue condition, represent another 
important issue for the therapeutic outcome [10,11]. 
Therefore, the synergy between CCT and tissue-
engineering approaches, able to increase the 
engraftment and regenerative potential of injected 
cells, in addition to their anti-remodeling capacities 
and the possibility to stimulate resident cells, could 
represent a beneficial and valid alternative [12]. In 
the present review, we discuss the therapeutic role 
of CPC population and provide an overview on the 
state of the art and recent advantages on scaffold-
based therapy for infarcted myocardium in order to 
understand which step will be the next to be taken to 
improve cardiac regenerative medicine.
2 CARDIAC ECM
ECM is a key functional tissue structure, including growth 
factors, fibrous proteins and glycosaminoglycans 
(GAGs) produced and secreted by resident cells, able 
to create an in vivo specialized microenvironment 
in which cells survival and biological activity is 
preserved [13]. In the heart, ECM provides structural 
and functional integrity, mediating the mechanical 
connect ion among cardiomyocytes, cardiac 
fibroblasts (CFs) and blood vessels, able to guide 
organ development and physiologic repair and to 
affect cardiac functions [14–16]. CFs, that together 
with endothelial cells represent the higher portion of 
resident non-myocyte cells, are able to produce ECM 
and, at the same time, maintain its homeostasis, 
through the production of matrix metalloproteinases 
(MMPs), a group of ECM-degrading enzymes able 
to break down all the protein components of the 
matrix, and the tissue inhibitors of metalloproteinases 
(TIMPs) [17,18]. Several pre-clinical and clinical studies 
have underlined that an imbalance in ECM remodelling, 
which means an alteration between the MMPs 
and TIMPs production and function, is detrimental 
in the failing heart [19–23]. In fact, this maladaptive 
remodelling, bringing to an altered arrangement 
and reduced cross-linking between collagen 
fibres, contributes to reduce systolic performance, 
decreased compliance and diastolic dysfunction in 
failing human heart [24]. Furthermore, inflammatory 
cytokines such as interleukin-1b (IL1b), interleukin-6 
(IL6) and tumor necrosis factor-α (TNFα) can promote 
the differentiation of CFs into collagen-producing 
myofibroblasts, increasing the relative amount of the 
stiffer collagen type I over the more compliant collagen 
type III [25–27]. The increase in myocardial stiffness, from 
a physiologic 10–20 kPa Young’s Modulus to a 50–200 
kPa range, leads to an autocrine feedback signalling 
able to support a mechanically induced fibrosis that 
ends up in chronic scarring process [28]. Furthermore, 
it has been demonstrated that during this cardiac 
adverse remodeling, variations in ECM composition 
and its mechanical features can interfere with the 
cardiogenic potential of resident or transplanted 
CPCs [29]. In this optic, ECM and ECM-like materials 
represent functional and biocompatible tools with a 
great potential to serve as natural or nature-mimicking 
scaffolds in the field of regenerative medicine [30,31].
3 CPCS AND HEART REGENERATION
The heart has been considered for a long time as 
a terminally differentiated organ with no intrinsic 
capacity to regenerate after myocardial injury. 
This concept is now being challenged and several 
evidences demonstrated that  into the adul t 
mammalian heart, both in normal and pathological 
conditions, myocytes are able to undergo mitosis and 
cytokinesis [32]. Furthermore, different resident cardiac 
progenitor cells (CPCs) populations have been 
identified both in the embryonic and adult heart and 
their potential use for cardiac regeneration has been 
deeply investigated for years [33].
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3.1 Embryonic CPCs
During the embryonic development, multipotent 
cardiovascular progenitors (MCPs), which derive 
from the mesodermal lineage, contribute to the heart 
formation in two ways [34]. On one side, the First Heart 
Field (FHF), which is the classical cardiac crescent 
consisting of T-Box 5 (TBX5) positive cells, is known 
to contribute to the formation of the left ventricle 
and, partially, of the atria. From the other side, the 
Second Heart Field (SHF), mainly composed of LIM-
homeobox Transcription Factor Islet-1 (ISL1) positive 
cells, contributes to the formation of the right ventricle, 
the outflow tract and the remaining parts of the atria [35,36]. 
Due to their ability to differentiate into cardiac and 
smooth muscle and vascular endothelium, MCPs 
represent a promising regenerative tool for heart 
repair [37,38]. In fact, embryonic stem cells (ESCs) have 
been deeply studied not only to investigate cardiac 
development and the function of human and murine 
heart cells, but also to determine the basic strategies 
of regenerative cell therapy [39–41]. Furthermore, several 
in vitro protocols have been developed to stimulate 
human ESCs differentiation in cardiomyocytes, 
providing a morphology and an expression profile 
similar to that of adult cardiomyocytes [42]. Briefly, 
cardiomyocytes markers are categorized in two 
principal groups: early and late differentiation. After 
5–6 days of differentiation, GATA Binding Protein 4 
(GATA-4), Isl1, and Kinase Insert Domain Receptor 
(KDR) become highly expressed. Later, between 8 
and 10 days of differentiation, the expression levels 
of NK2 homeobox5 (NKX2.5), Tbx5, Myocytes-
Specific Enhancer Factor 2C (MEF2C) and HAND1/2 
reach an expression peak together with an increase 
in myofilament-related gene expressions, such as 
Troponin T2 (Tnnt2) and Myosin Heavy Chain 6 
(Myh6) [43]. Nevertheless, despite MCPs high plasticity, 
their introduction into the clinical trial/therapeutic 
scenario is affected by several problems, in particular 
ethical issues, the genetic variability, the risk of 
immune rejection and the tumorigenic possibility [44].
3.2 Adult CPCs
Even if their physiologic role in homeostasis and 
activation after injury still remains unclear, CPCs can 
be isolated from adult human and mammalian hearts 
with different approaches [45–47]. For example, side 
population cells (SP) are defined by their ability to 
efflux the DNA-binding dye Hoechst 33342, whereas 
Sca1+ population is characterized by the expression 
of the stem cell antigen-1 [48,49]. Interestingly, in 2004 it 
has been demonstrated for the first time that human 
CPCs can be isolated, starting from explant cultures 
of percutaneous endomyocardial biopsy specimens, 
through their capacity to form spontaneously 3D 
spherical clusters, called cardiospheres (CSps) [50–53]. 
CSps represent a perfect niche microenvironment 
in which it is possible to recognize, according to 
their expression pattern, two distinct compartments. 
The core, in which cells are characterized by a high 
proliferation rate, presents a cardiac progenitor 
immunophenotype dominated by the expression of 
stem cell and cardiomyocyte-related antigens, such 
as c-KIT, GATA-4, NKX2.5, CX43 and OCT4. On 
the contrary, peripheral cells are characterized by a 
more committed expression profile into endothelial, 
mesenchymal, or cardiomyogenic lineages (CD105, 
MHC, TNI, CD31, CD133, MDR1) [52,54]. CSps can be 
expanded in monolayer as CSps derived cells (CDCs) 
to obtain a culture enriched in CPCs, previously selected 
through the CSps formation step [51]. CDCs are defined 
by clonal growth capacity and, phenotypically, by 
several characteristic markers, such as α-SMA, 
CX43 and CD105 that positively identify more than 
80% of CDCs, resulting negative, at the same time, 
for hematopoietic and endothelial progenitor cell 
markers [55]. Interestingly, CDCs can acquire a mature 
cardiomyocyte phenotype when co-cultured with 
neonatal rat ventricular myocytes (NRVMs) [55]. Although 
it has been analysed the therapeutic potential 
of other non-cardiac stem cell sources, such as 
embryonic cells, bone marrow-derived mesenchymal 
stem cells, endothelial progenitor cells, myoblasts 
and induced pluripotent stem cells, many evidences 
underlined that resident CPCs, especially CDCs, 
represent the better candidate for cardiac regenerative 
medicine [5,56–59]. In 2012, Li et al., using a mouse 
model of myocardial infarction (MI), demonstrated 
that the functional outcome of CDCs transplantation 
was superior to the transplantation of bone marrow 
mesenchymal stromal cells and adipose-derived 
regenerative cells [58]. Subsequently, other preclinical 
studies confirmed that CDCs therapy has multiple 
beneficial effects on the damaged myocardium, such 
as enhancement of cell survival, increase of blood 
supply and viable mass, reduction of inflammation 
and scar size and, in acute MI pig models, 
prevention of ischemic injury after reperfusion [60–65]. 
These encouraging preclinical results have paved 
the way to CDCs-based clinical trials. In 2012, the 
CADUCEUS study (NCT00893360) investigated the 
intracoronary administration of autologous CDCs 
after acute myocardial infarction [66]. In the 6-month 
follow-up, the safety of the cells was demonstrated 
in association with a reduction of the infarct scar 
size and an increase in myocardial viability and 
contractility [66]. Furthermore, after 1 year from the 
treatment, even if ventricular volumes and left 
ventricular ejection fraction (LVEF) did not increase, 
myocardial regeneration has been achieved, 
strengthened the therapeutic potential of CDCs [67]. 
In the same year, another clinical trial started, the 
ALLSTAR study (NCT01458405), in order to evaluate 
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the effect of allogeneic CDCs on scar size in patients 
with post-MI ischemic left ventricular dysfunction [68]. 
Unfortunately, the study is still in progress and results 
are not yet available. Interestingly, even if CPCs show 
a high differentiation potential in vitro, recent studies 
suggest that the in vivo direct differentiation following 
transplantation is not the primary mechanism by 
which these cells promote cardiac recovery [6]. In 
fact, a great proportion of CPCs therapeutic effects 
were shown to be attributable to indirect mechanisms 
of action able to exert protective and beneficial 
effects on the endogenous tissue. In a comparative 
study, it has been analysed the CPCs secretome 
profile, consisting of humoral factors, proteins, 
and molecules, underlining a highly complex and 
biological activity able to provide significant paracrine 
benefits than other progenitor populations, such as 
the bone marrow or adipose tissue [58]. Indeed, CPCs 
secretome exerts significant anti-apoptotic effects, 
promotes the recruitment of endogenous progenitors 
and the activation of endogenous cardioblasts [69–71]. 
In this context, also CPCs-derived exosomes are 
able to exert, once released in the extracellular 
microenvironment, positive therapeutic effects through 
multiple mechanisms interacting with different target 
cells, such as endothelial cells and cardiomyocytes [72–74]. 
Overall, despite all these encouraging results many 
critical issues, including the challenges of electrical 
coupling, undetermined mechanism aspects and, 
above all, the long term engraftment and survival 
of injected cells, should be addressed before CPCs 
could be considered as a strong therapeutic tool for 
regenerative medicine applications [75].
4 TISSUE ENGINEERING FOR 
CARDIAC REGENERATION
Tissue engineering could be defined as a synergistic 
cooperation, between biotechnological, biomedical 
and engineering knowledges and applications, which 
aims to regenerate damaged tissues and/or organs. 
In the cardiac regenerative medicine field, one of 
the most important issues of tissue engineering is 
the development of functional artificial tissues and 
organs. The ideal engineered product has to provide 
an adequate cellular niche microenvironment able 
to mechanically support and direct cell growth, 
di fferent iat ion and engraftment,  protect the 
transplanted cells from the hostile infarcted tissue 
environment and, as an outcome, to promote tissue 
remodeling/regeneration [12,76]. For all those reasons, 
biocompatibility, biodegradability and permeability 
represent the unavoidable characteristics that the 
biomaterial must possess [77]. 
4.1 Polymers for cardiac tissue engineering
Polymers, characterized by a wide range of 
compositions and, thus, properties, represent one 
of the most used classes of biomaterials to recreate 
EMC-mimicking scaffolds for cardiac regeneration. 
In general, polymers can be classified in synthetic 
or natural (Table 1). Briefly, synthetic materials, 
such as Polyglycolic acid (PGA), polylactic-l-
acid (PLLA), polylactic glycolic acid (PLGA) and 
polyurethane (PU), that are extremely malleable, 
are not always biodegradable and often prevent 
vascular and parenchymal cell attachment and 
infiltration [78,79]. Besides, natural polymers, or 
biopolymers, such as collagen, elastin, chitosan, 
cellulose and hyaluronic acid, even if exhibit a 
higher degree of biocompatibility and promote 
cell migration and differentiation, present a low 
mechanical strength for cardiovascular application [80]. 
Therefore, it has been proposed the combination 
of synthetic and natural biomaterials to improve 
the weakness of each polymer to create a scaffold 
with better properties [79,81]. Nowadays, one of the 
most promising approaches investigated for cardiac 
tissue engineering involves the use of bioactive 
glasses (BGs) [82]. BGs, since their discovery by Hench 
et al in 1969, have gained much attention in tissue 
engineering due to their highly biocompatibility 
and bioactivity and are recognized as the second 
generation of biomaterials with the ability to bond 
to the living tissues [83]. Based on their composition, 
BGs can be categorized as silicate-based glasses, 
borosi l icate and borate-based glasses, and 
phosphate-based glasses. Recently, BGs has been 
considered as suitable materials for cardiac tissue 
engineering, especially in the form of nanoparticles 
in combination with biocompatible polymers acting 
as soft matrices [82,84].
Table 1. Differences between synthetic and natural polymers commonly used in cardiac tissue engineering.
Biodegradability Malleability Bioactivity
Synthetic polymers Low High Yes
Natural polymers High Low Yes
Combination of synthetic and natural polymers High High Yes
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4.2 Native decellularized ECM as a biomaterial
In the last years, many studies investigated the 
creation of autologous biological scaffolds composed 
of native ECM, derived from the decellularization of 
tissues or organs, in order to provide tissue-specific 
ECM compositions, which can influence the behavior 
of resident and/or transplanted cells [85,86]. Recently, 
Seo et al. developed a detergent-free decellularization 
protocol based on supercritical carbon dioxide and 
ethanol co-solvent (scCO2-EtOH) method able 
to prevent ECM structure disruption. They tested 
this decellularized ECM (dECM) on rat heart tissues, 
demonstrating that heart-derived dECM with scCO2-
EtOH treatment, compared to a collagen control group, 
represented a promising angiogenic material for healing 
in ischemic disease [87]. In general, the decellularization 
process, removing cell components, is able to leave 
unchanged tissue architecture, ECM components and, 
thus, mechanical properties [88,89]. In addition, eliminating 
antigenicity, in case of xenogenic or allogeneic transplant 
it reduces the possibility of inflammatory and immune 
responses [90–94]. A variety of non-cardiac tissue types 
have been tested as decellularized ECM source in order 
to repair myocardium after an ischemic injury, such as 
small intestine submucosa or urinary bladder matrix [95–97]. 
However, it has been demonstrated that cardiac ECM 
exhibits tissue-specific composition and organization, 
therefore the utilization of an ECM from non-cardiac 
tissues may fail to provide proper stimulations to cells 
in the myocardium [98,99]. Nowadays, pericardial and 
myocardial tissues represent the principal cardiac-
source for ECM [100,101]. The pericardium is a double-
walled fibrous sac, primarily composed of collagen 
and elastin, that contains the heart and the roots of 
the great vessels, fixing them to the mediastinum, 
and it is able to confer protection against infections 
and lubricates the heart  [95,102]. Myocardium is the thick 
contractile middle layer of the heart wall composed of 
muscle cells. Myocardial ECM is principally composed 
of a mixture of different collagen types (80% type 
I, 10% type III, < 5% type V) in addition to a small 
amount of laminin, elastin and fibronectin [103]. 
4.3 3D scaffolds
Despite contributions in biomedical research and the 
development of more complex 2D culture platforms, 
it is difficult to predict, recapitulate and understand 
cell-cell interactions and functions, naturally designed 
for a 3D environment, in a bi-dimensional context. 
Cardiac ECM, secreted by resident cells, consists 
of structural and functional three-dimensional 
molecules-based organization that establish cardiac 
ultrastructure and microenvironment [104]. In this optic, 
3D scaffolds, could represent a perfect physiological 
and pliable pattern to promote an effective tissue 
remodelling and regeneration in damaged cardiac 
tissues, enhancing in resident and/or transplanted 
CPCs chemotaxis, proliferation and differentiation [105]. 
In terms of patch architecture many different systems 
have been investigated and are available for scaffold 
creation. In 2002, Taylor et al. demonstrated that 
3D biodegradable collagen sponge-based scaffold, 
composed of interconnected micropores, with notable 
fluid absorption and hydrophilicity, was able to 
maintain viable human cardiac valve interstitial cells 
(ICs) and to enhance the capacity of those cells to 
express their original phenotype, making this scaffold 
suitable to resemble a valve leaflet [106]. A different 
approach is based on mesh-based scaffold, in which 
biomaterial fibers are braided in a 3D structure with 
uniform porosity and dimensions similar to the ones 
naturally occurring in the ECM. A comparison of 
the structural and biological features of a collagen 
fibrous ball-of-thread-like versus a gelatin trabecular 
sponge-like bio-constructs, seeded with human 
CSps, demonstrated that both scaffolds, despite 
their structure or composition, recreate a more 
pro-survival and cardiac-specific differentiative 
microenvironment than the normal in vitro culture 
protocols [107]. Recently, it has been compared, both 
in vitro and in vivo, the effect of a biodegradable and 
non-toxic PU-based scaffold, grafted with laminin-1 
(PU-LN1) or gelatin (PU-G), populated with human 
CPCs [108]. Compared to the PU-G, used as control, 
PU-LN1 is able to highly promote cells proliferation, 
protection from apoptosis and expression of 
differentiation markers for cardiomyocytes, endothelial 
and smooth muscle cells. Furthermore, once LN1 
scaffolds are implanted subcutaneously in a mouse 
model of MI, they are able to minimize inflammation 
and, stimulating blood vessel density around them, to 
perfectly integrate with the host tissue [108]. Similarly, 
Wang et al. developed, for the first time, a 3D 
collagen-elastin scaffold, for heart valve engineering, 
without chemical crosslinker and assembled by 
temperature-triggered gelling [109]. Whoever the 
reduced cell toxicity, the novelty of this approach 
consists in the co-culture of valvular interstitial cells 
(VICs), encapsulated in the matrix, with valvular 
endothelial cells (VECs), cultured on the surface 
of the 3D structure. Thereby, this scaffold was able 
to stimulate cell proliferation, to increase actin 
filaments and to improve integrin β1 expression, 
representing a novel platform to better study and 
understand, cell-cell or cell-matrix interactions 
and, possibly, to improve cardiac valve tissue 
engineering [109]. As said previously, native ECM 
could represent a suitable mechanical and biological 
environment able to ensure cell engraftment and 
to improve therapeutic and regenerative properties 
of resident and transplanted cells [29,110,111]. Several 
studies demonstrated the positive effects of cardiac 
dECM patch in damaged cardiac tissue. In 2016, 
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a porcine cardiac dECM was implanted in acute 
and 8-weeks chronic MI rat models [112]. In both 
conditions, dECM was rapidly vascularized and was 
able to promote an improvement in cardiac function 
through the recruitment of resident CPCs, their 
stimulation towards the cardiomyocyte lineage and 
their arrangement in partially striated and immature 
muscle fibers [112]. Furthermore, in the last years, even 
if the debate on the benefits of this method is still in 
progress, it has been investigated the possibility to 
combine in vitro cardiac dECM with CPCs and to apply 
this “cellularized” patch for in vivo treatments [113–115]. In 
2014, Rajabi-Zeleti et al. fabricated a 3D macroporous 
cardiac patch from human decellularized pericardium 
membranes (dPM) [116]. They demonstrated that the 
dPM macroporous scaffold is able to enhance the 
proliferation, viability, migration and differentiation 
of CPCs in vitro. Furthermore, after an in vivo 
subcutaneous implantation, besides the improvement 
in cells differentiation, the dPM scaffold was able 
to stimulate angiogenesis and to avoid immune 
rejection [116]. Recently, a 3D macroporous cardiac patch 
from solubilized myocardium dECM with the addition 
of chitosan (CS) has been successfully designed and 
fabricated [110]. The novelty was represented by the 
possibility, modifying the percentage of solubilized 
dECM and CS, to modulate the stiffness of the 
scaffold according to the requirements. CPCs seeded 
on this malleable microporous myocardium scaffold 
present a high proliferation rate and viability in addition 
to a significant increase in expression of early cardiac 
markers [110]. Taking together, all these results could 
be give reasons to investigate and to elucidate how 
fabricated scaffold could be used to stimulate CPCs 
differentiation into cardiomyocytes, aiming to create 
the perfect dECM-derived cardiac regenerative patch.
4.4 Hydrogels
One of the principal aim of cardiac regeneration is 
to repair ischemic tissues, stimulating the formation 
of new blood vessels, through the delivery of 
angiogenic growth factors, stem cells or expansion 
of pre-existing cells. Despite the encouraging results 
previously analyzed, one of the problem associated 
with the use of 3D patch for cardiac repair is the 
lack of a complete vascularization able to affect the 
thickness of the scaffold and, as a consequence, cells 
viability [117]. Furthermore, the necessity to develop 
minimally invasive techniques requires the setting 
up of alternatives. In this optic, injectable hydrogels 
represent the most investigated biomaterials 
forms for both in vitro and in vivo cardiac tissue 
engineering (Table 2) [118,119]. Hydrogels can be defined 
as viscoelastic system, composed of a natural or 
synthetic extensive water-swollen polymeric network, 
that can be injected in liquid state and then able 
to form a solid gel in situ [120]. In 2004, Christman 
et al. investigated, for the first time, the effects of an 
injectable biopolymeric fibrin scaffold to deliver cells 
directly into the infarct wall of MI model rats [121]. Their 
rationale was that the direct injection in the infarcted 
myocardium of cells, in this case skeletal myoblasts, 
would increase cell transplant retention and survival 
within the infarct. Even if fibrin glue was not able to 
increase cells retention, the injection of this hydrogel 
was able to promote cells survival and blood supply 
to the ischemic myocardium leading to a reduction of 
infarct size and myocardial remodeling [121]. In addition, 
the same group demonstrated that an injectable porcine 
ventricular ECM-derived hydrogel was able to promote 
in vitro proliferation, survival and cardiogenic potential 
of embedded human Sca1+ CPCs population [122]. The 
subsequent injection of the hydrogel in an induced 
MI rat model resulted in a reduced cardiomyocyte 
apoptosis, cardiac hypertrophy and fibrosis. On 
the other side, the resulted increase in resident 
CPCs recruitment, in cardiac transcription factor 
expressions and in the neovascularization of the 
infarcted tissue, has led to an improvement in global 
cardiac functions and hemodynamics [123–125]. These 
results in accordance with the needed to provide 
increasingly effective therapeutic tools have triggered 
a still ongoing clinical trial (NCT02305602) that 
evaluates the safety and feasibility of the porcine 
myocardial dECM-derived hydrogel delivered, in a 
minimally-invasive procedure, via catheter to the 
damaged cardiac tissue in patients after myocardial 
infarction [125–127]. It has been deeply demonstrated 
that human cardiac dECM-derived hydrogels support 
in vitro proliferation and differentiation of pluripotent 
stem cells along the cardiomyocyte lineage in addition 
to a cytoprotective effect [128,129]. Nonetheless, the 
porcine dECM application is favoured than human 
one because of the rarity of collecting healthy human 
hearts, the significant patient-to-patient variability 
and, most of all, the aging-related alteration in ECM 
composition [27,130,131]. Either way, other clinical trials 
have been developed to investigate the in vivo 
therapeutic efficacy, safety and feasibility of other 
hydrogel compositions [126,132]. For example, the 
PRESERVATION-1 trial (NCT01226563) evaluated 
the safety and effectiveness of an alginate hydrogel, 
intracoronary injected, for the prevention of ventricular 
remodeling and congestive heart failure after MI [133,134]. 
Furthermore, despite the hydrogel composition, the 
suitable injection site represents another issue to be 
investigated. In a recent study by Garcia et al., it has 
been tested on a pig model of atrial fibrillation (AF) 
the efficacy of amiodarone, an effective lipophilic 
medication approved for rhythm control but with 
a significant systemic toxicity, encapsulated in a 
PEG-based hydrogel (50 mg amiodarone/5 mL 
gel) and injected directly on the atrial pericardium. 
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They demonstrated that pericardium hydrogels can 
deliver therapeutics directly to the heart enabling 
a continued release of drug for several weeks and 
reducing off-target organ accumulations [135]. These 
results highlight the possibility to use pericardium 
as an alternative therapeutic site for treatment 
strategy for AF and other cardiovascular diseases. 
Interestingly, Zhang et al., aimed to test in vitro the 
efficacy of the pretreatment with pericardial fluid 
(PF) from rats with myocardial infarction (PFMI) on 
CSps and to assess, for the first time, the therapeutic 
in vivo effect on rat models of MI by administering 
these pretreated CSps, embedded in a commercial 
hydrogel, in the pericardial cavity [136]. In vitro 
experiments demonstrated that PFMI pretreatment 
enhanced CSps survival and their commitment 
in cardiac muscle cells. Interestingly, the in vivo 
pericardial application of hydrogel with functionally 
enhanced CSps demonstrated that these cells could 
differentiate in cardiac myocytes and, in a paracrine 
way, to improve cardiac function and myocytes 
survival, to stimulate angiogenesis into the infarcted 
myocardium and to reduce myocardial fibrosis [136].
Table 2. Principal advantages and disvantages of 3D Scaffold vs. Hydrogel.
Advantages Disvantages
3D scaffold
● Three-dimensional molecules-based organization 
similar to natural ECM
● Biodegradability
● Malleability
● Bioactivity
● Lack of a complete vascularization
● Invasiveness surgical procedure
Hydrogel
● Minimally invasive techniques requires
● Bioactivity
● Biodegradability
● Less mechanical strength
● Pathogen risk potential
4.5 Bioprinting
Bioprinting technique, earlier called cytoscribing, 
represents the last frontier in cardiac t issue 
engineering and could be defined as computer-
aided additive biofabrication of 3D cellular tissue 
constructs [137–139]. This quickly progressing automated 
technology allows to strictly controlling the micro 
and macro-architecture of replacement tissues and 
organs providing high reproducibility and precise 
control [140]. Up to date, many tissue types, such as 
bone, vasculature, neural tissue and cardiac muscle, 
have been created starting from autologous and 
patient specific primary or stem cells [141–143]. The 
basic unit of the entire printing process is the so-
called “bioink” that has to be biocompatible and stable 
from a mechanical and structural point of view [144,145]. 
Generally, the printable material is composed by 
living cells, such as embryonic, adult, or induced 
pluripotent stem cells, proteins and other active 
biological molecules loaded into a matrix, mimicking 
the ECM. According to their base materials, bioinks 
could be divided in two principal groups: scaffold-
based and scaffold-free bioinks (Table 3) [139,146–148]. 
In the first group, cells are seeded within natural or 
synthetic hydrogels, such as collagen, fibrin and 
polyethylene glycol, or in dECM [146,149]. On the other 
side, cells in the scaffold-free bioinks are printed 
without matrix support and the ability to deposit their 
own ECM is exploited to confer support for cell-cell 
communication and proliferation to create strands 
or spheroids [147,148]. Despite the selected bioink, 
up-to-date three different bioprinting processes 
are available [150]. The technical gold standards are 
represented by viability, spreading and proliferation of 
cells, in addition to the functionality of the bioprinted 
constructs [151]. Droplet-based bioprinting (DBB), 
based on a two-dimensional inkjet printing, was 
the first developed and it is still the most commonly 
used methodology. Even if DBB is cost-effective 
and allows obtaining an 85% of bioink-cell viability, 
the lower resolution, due to the wide-range of drop 
size (50–300 µm), represents an important technical 
limitation [152,153]. In the Extrusion-based bioprinting 
(EBB), bioink is deposited in cylindrical lines, instead 
of droplets, by a controlled fluidic dispensing system. 
EBB offers a great flexibility in printing a wide range 
of bioinks, such as spheroids or tissue strands, with 
a considerable print speed, encouraging scalability 
and clinical translation. However, from a practical 
point of view, the resolution of printed features is 
still very low and the percentage of cell viability is 
around the 80% [153,154]. Finally, in the Laser-based 
bioprinting (LBB), also known as Stereolithography-
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based bioprinting (SBB), a laser pulse induces the 
bioink to acquire a drop shape in order to form 3D 
constructs. Throughout this artifice, it is possible to 
obtain a higher precision and resolution, mechanical 
stress is reduced and cell viability stands around 
the 95% [153]. Unfortunately, at least for the moment, 
the high costs and the complexity of the laser system 
make this technology not easily accessible. From a 
practical point of view, currently bioprinting research for 
cardiovascular tissue regeneration largely focuses on 
the myocardium, heart valves, and vasculature [150]. For 
example, Gaetani et al. evaluated the therapeutic 
potential of a 3D-printed patch composed of human 
Sca1+ progenitor cells in a hyaluronic acid/gelatin 
(HA/gel) based matrix, transplanted in a mouse 
model of MI. They observed that the application of 
the patch led to a significant reduction in adverse 
remodeling and preservation of cardiac performance. 
Furthermore, the matrix supported the long-term 
in vivo survival and engraftment of CPCs, which 
exhibited a temporal increase in cardiac and 
vascular differentiation markers over the course of 
the 4 week follow-up period. Overall, they developed 
an effective and translational approach to enhance 
CPCs delivery and action in the heart [155]. Wang 
et al. have recently provided another example of 
the feasibility of bioprinting in achieving functional 
cardiac tissues [156]. They integrated isolated neonatal 
rat ventricular cardiomyocytes in a composite 
hydrogels preparation and dispensed this bio-mixture 
to form a string form or patch form. Interestingly, after 
1 week in culture, they observed a spontaneous and 
synchronous beating of bioprinted cardiac tissues 
and, in parallel, the formation of dense and uniformly 
aligned heart muscle bundles. Differently, Ong et al. 
proposed a culture protocol for 3D bioprinting of 
cardiac tissue without the use of biomaterials [157]. 
Firstly, they co-cultured isolated cardiomyocytes, 
endothelial cells and fibroblasts in low attachment 
96-well plates leading to the formation of spontaneous 
beating spheroids. The possibility to create different 
mixtures, which differ in term of cell type’s percentage, 
allows obtaining, depending on the purpose, many 
different types of printed cardiac patches, with 
distinctive histological and mechanical properties. 
Furthermore, the innovative feature of this protocol 
was the possibility to pick up individual spheroids using 
vacuum suction and position them on a needle array. 
Accordingly, spheroids could be precisely positioned 
in any desired configuration and fused together to 
create a scaffold-free functional 3D bioprinted patch 
with mechanical integration of component spheroids. 
As said previously, bioprinting has been explored also 
for cardiac valve construction in order to enhance 
physiological characteristics, such as durability or 
anticoagulation, compared to traditional mechanical 
and biological prosthesis valve replacements [158]. 
Therefore, many evidences, underlined how, through 
bioprinting approaches, it is possible to obtain a better 
ECM deposition, an upregulation of muscle actin and a 
strong human aortic valvular interstitial cells (HAVICs) 
phenotype [150,159,160]. To summarize, compared to 
traditional therapeutic strategies, 3D bioprinting may 
offer a unique approach for creating complicated 
cardiovascular implants with biomimetic features, 
which are capable of recapitulating both the native 
physiochemical and biomechanical characteristics 
of the cardiovascular system. Furthermore, the 
current implementation of this technique with the 
latest pre-vascularization technologies will lead to 
the improvement of blood perfusion throughout the 
engineered tissue. For this reason, in the near future, 
it will be implemented a physiological mimicry of 
human cardiovascular tissues in order to be applied 
for an effective drug development, therapeutic 
approaches and, through the reconstruction of 
fully functional organ, to overcome the shortage of 
organ transplantation [150,161,162].
Table 3. Advantages and disvantages of Scaffold-based and Scaffold-free bioinks.
Materials Advantages Disvantages
Scaffold-based 
bioinks
Natural or synthetic 
hydrogels or dECM
● Easy bioprintability
● High resolution
● Economical
● Toxicity
● Degradation
● Limited cell-cell interactions
● Medium tissue biomimicry
Scaffold-free 
bioinks
Cells are printed 
without a matrix 
support
● Rapid tissue maturation    
   and generation
● High tissue biomimicry
● Difficult bioprintability
● Need for high cell numbers
● High costs
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5 CONCLUSIONS
Enormous progress has been made, in the last 
decades, in cardiac tissue engineering, rendering 
the clinical application of biomaterials increasingly 
plausible. However, the concepts discussed in 
the present review represent just a portion of the 
great amount of investigations that are still ongoing 
to insert cardiac tissue engineering in the clinical 
routine. Actually, the complexity of the heart system, 
not only because of its mechanical and structural 
function but also due to its electrical properties 
as well, still need many efforts to implement our 
knowledge of the entire panel of variables that 
influence its regeneration and repair mechanisms. 
For these reasons, it would be desirable, in the near 
future, to support scientific cooperation in order to 
build consensus in all the aspects underlined here, 
starting from the detection of the best material to 
the suitable scaffold production technique, without 
overlooking the selection of the powerful cellular 
therapeutic tool. In fact, only in this way many issues 
could be solved boosting cardiac tissue engineering 
as an effective therapeutic choice for millions of 
heart patients.
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